Takata Y, Tsuchihashi T, Nakamura S, Hirota Y
Department of Internal Medicine, Kyushu Dental College, Japan.
Clin Cardiol. 1995 Jul;18(7):408-11. doi: 10.1002/clc.4960180709.
Denopamine was orally administered for more than 12 months to patients with chronic heart failure on maintenance hemodialysis. The plasma level in subjects treated with denopamine at 30 mg/day tended to be higher than that in subjects on 15 mg/day. There was no gradual increase in plasma level as the duration of therapy prolonged. Left ventricular end-diastolic and end-systolic diameters as well as ejection fraction on echocardiography showed a tendency to be improved by denopamine. Similarly, the cardiothoracic ratio was improved temporarily. No adverse effects were detected by electrocardiography and laboratory tests. These observations suggest that denopamine is safe and effective for hemodialysis patients with chronic heart failure.
对维持性血液透析的慢性心力衰竭患者口服多巴胺超过12个月。接受30毫克/天多巴胺治疗的受试者血浆水平往往高于接受15毫克/天治疗的受试者。随着治疗时间延长，血浆水平没有逐渐升高。超声心动图显示的左心室舒张末期和收缩末期直径以及射血分数有被多巴胺改善的趋势。同样，心胸比率也有暂时改善。心电图和实验室检查未检测到不良反应。这些观察结果表明，多巴胺对血液透析的慢性心力衰竭患者是安全有效的。
